Pall Launches New Products to Increase Supply of Safe Blood Without Increasing Cost



    EAST HILLS, N.Y., October 22 /CNW/ - Pall Corporation (NYSE:   PLL)
launches the new Acrodose(TM) PLus System to ensure patients receive the
safest possible platelet transfusion -- no matter what type of system blood
centers use to collect donated blood. In addition to increasing safety and
availability of blood, Pall's new technologies enable more efficient use of
blood components by putting an end to wasting valuable and limited donations
without increasing hospital or blood center costs. Along with the Acrodose
PLus System, Pall is also introducing a new approach that makes universal
blood collection possible. The new technologies are being showcased at the
AABB annual meeting for transfusion medicine in Anaheim, California this week.

    The Acrodose PLus System enables all blood centers -- no matter what type
of collection system they currently employ -- to provide patients with an
Acrodose(SM) Platelet, a transfusion-ready, therapeutic dose of the highest
quality whole-blood derived platelets available today. Pall was granted FDA
clearance for marketing the Acrodose(TM) PL System two years ago; initially
applicable to blood centers in the U.S. that use a Pall collection and
filtration system for whole-blood platelet collection. The new Acrodose PLus
System provides blood centers with greater operational flexibility, and allows
them to use any collection system for whole blood platelet preparation --
ultimately giving more patients the benefits of an Acrodose Platelet. The
expanded use of the Acrodose PLus with all collection systems is especially
valuable for blood centers that cannot currently change their established
blood processing practices due to procedural or contractual obligations,
validation and other requirements.

    The original Acrodose PL System addressed concerns regarding platelet
shortages in many parts of the country due to a growing dependence on
apheresis (single-donor) platelets, and platelet safety, especially bacterial
contamination, associated with whole-blood derived platelets. (Bacterial
contamination of platelets is a leading cause of sickness and death from a
blood transfusion.) With the Acrodose PLus System, all blood centers and
hospitals will no longer have to be concerned about a lack of sufficient
quantities of platelets for life-saving transfusions or employ platelets that
are not tested for bacterial contamination using the most sensitive culture
detection methods.

    "Our goal is to help blood centers and hospitals enhance their ability to
provide patients with access to the safest blood possible for transfusion. We
do this by developing innovative technologies that they can efficiently put
into practice, without adding to their myriad burdens and challenges, such as
cost, which all too often can deter advances in blood processing," says Allan
Ross, President of Pall Medical and former Chief Operating Officer, American
Red Cross Biomedical Services. "With the Acrodose PLus System, a two-tiered
level of platelet quality can truly become a practice of the past as all blood
centers and hospitals will no longer have to trade off between platelet safety
and availability."

    The Acrodose Platelet is a new generation platelet product with
significant advantages -- improved safety, increased availability and lower
cost. Acrodose Platelets are leukocyte reduced (white blood cells removed),
matched for blood type and tested for bacteria using a sensitive culture-based
system. Clinically equivalent to a single donor platelet (in terms of platelet
count and quality) but at a lower cost, an Acrodose Platelet enables blood
centers to tap into the abundant but often discarded resource of whole blood
platelets without sacrificing safety.

    Acrodose Platelets benefit patients who require life-saving platelets for
treatment of cancer, leukemia, blood disorders, bone marrow or organ
transplants, accident, burn or trauma as well as blood collection facilities
that collect, pool, and test the platelets, and the hospitals that transfuse
them. Patients can be assured that they are receiving the highest quality of
platelets available. Hospital and blood centers will be able to efficiently
and conveniently provide optimal blood products, not waste valuable whole
blood donations and achieve this without adding to their costs.

    Universal Collection - - A New Approach to Prevent Wasting Valuable Blood

    With the availability of the Acrodose PLus System, Pall is also
introducing a new approach that makes universal blood collection possible so
that blood centers will no longer have to determine in advance what type of
blood components to collect. Most often when collections are done, especially
by mobile units, blood centers have to take their best guess on which blood
components are needed by hospitals for their patients -- red cells, plasma
and/or platelets-- and set up their collections to do that. By using the new
Acrodose PLus System with the Pall Leukotrap(R) RC System with RC2D Filter,
much of that guesswork is eliminated. Together they allow blood collection
facilities to collect whole blood with one universal collection and filtration
system and make the determination of which components to process after they
return -- closer to real time when the hospital orders their blood components
based on actual patient needs.

    The Leukotrap RC System with RC2D Filter gives blood centers greater
flexibility in helping to meet transfusion needs, conserve blood through
enhanced processing and avoid problems of wasting valuable blood resources.
The universal aspect of this collection system gives them options on which
blood components to process while also maximizing blood component return.
After collection, based on actual needs, blood centers can choose to process
the donated blood one of two ways. The first way is to manufacture red cells
and plasma. In this case, the Leukotrap RC System with RC2D Filter provides
for more that ten percent additional plasma than traditional whole-blood
collection systems. The alternative option is to process some of the donated
blood into non-leukocyte reduced platelets, a conventional amount of plasma as
well as red cells. In this case, the non-leukoreduced platelets can then also
be processed with the Acrodose PLus to make an Acrodose Platelet.

    Demand for blood components can change daily, sometimes hourly, depending
upon circumstances or emergencies. Both plasma and platelets are precious
blood components and are becoming increasingly more valuable with the
institution of new restrictions on the donor pool to reduce potentially fatal
diseases such as TRALI (transfusion-related acute lung injury). Additionally,
platelets whose main function is to aid in clotting have a very short life
span (5 to 7 days prior to being discarded). Plasma is the liquid portion of
blood which transports blood cells, water and nutrients to the body's tissues
and also contains many proteins that help the blood to clot and fight disease.

    About Pall Corporation

    Pall Corporation is the global leader in the rapidly growing field of
filtration, separation and purification. Pall is organized into two
businesses: Life Sciences and Industrial. These businesses provide
leading-edge products to meet the demanding needs of customers in
biotechnology, pharmaceutical, transfusion medicine, energy, electronics,
municipal and industrial water purification, aerospace, transportation and
broad industrial markets. Total revenues for fiscal year 2007 were $2.2
billion. The Company's headquarters are in East Hills, New York, with
extensive operations throughout the world. For more information, visit Pall at
http://www.pall.com.

    Editor's Notes:

    --  Visit Pall Booth #520 at AABB Annual Meeting & TXPO 2007 in the
Anaheim Convention Center, Anaheim, California and see how Pall Medical is
helping blood centers "Redefine the Business of Blood."

    --  Photos and information about the Acrodose(TM) Plus System are
available on http://www.pall.com/corporate_43996.asp.

    MULTIMEDIA AVAILABLE:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5522802




For further information:

For further information: Pall Corporation Marcia Katz Director of Public
Relations Telephone: (516) 801-9851 Email: marcia_katz@pall.com

Organization Profile

PALL CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890